Exchange: NASDAQ·Updated 07:30 PM EST

WGS News

News
all
press releases
GeneDx (NASDAQ:WGS) Shares Climb 8.8% - What's Next?
GeneDx (NASDAQ:WGS) Shares Climb 8.8% - Here's What Happened...
MarketBeat
GeneDx (NASDAQ:WGS) Shares Climb 8.8% - What's Next?
GeneDx (NASDAQ:WGS) Shares Climb 8.8% - Here's What Happened...
MarketBeat
More News
BTIG Research reiterated a "buy" rating and issued a $85.00 price target on shares of GeneDx in a research report on Wednesday...
MarketBeat
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that its Board of Directors has appointed Everett Cunningham as Chief Executive Officer and a member of the Board, effective on or before December 15, 2026. Mr...
Business Wire
Zacks Research upgraded shares of GeneDx from a "hold" rating to a "strong-buy" rating in a research note on Monday...
MarketBeat
GeneDx (NASDAQ:WGS) Shares Down 7.4% - Here's What Happened...
MarketBeat
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced that company management will participate in upcoming investor conferences: 2026 Jefferies Global Healthcare Conference London, UK Fireside Chat: Tuesday, November 17 at...
Business Wire
GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced new research to be presented at the National Society of Genetic Counselors (NSGC) 2026 Annual Conference, November 1114. Across four scientific posters and three educational...
Business Wire
Groupon plunged 20% premarket after missing quarterly earnings and sales estimates, while Digital Turbine, Daqo and others also traded lower.read more...
Benzinga
GENEDX HOLDINGS (WGS) delivered earnings and revenue surprises of +300.00% and +0.82%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
GeneDx Holdings Corp. (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today reported its financial results for the third quarter of 2026. Our Q3 results reflect profitable execution in a growing market, as we translate the rising demand...
Business Wire

Advertisement|Remove ads.